Sam – Page 189 – biolegacy

Spectris Snaps Up Concept Life Sciences in £163M Deal

Post author:Sam
Post published:January 25, 2018
Post category:BioPharma

Concept will become a separate operating company within its Materials Analysis segment where it has strong synergies with the activities of Malvern Panalytical. Source: BioSpace

Ballsy Celgene Continues to Tread Carefully Into Neurosciences

Post author:Sam
Post published:January 25, 2018
Post category:BioPharma

The company made some bold moves this month in acquiring Juno and Impact Source: BioSpace

Novelion to Cut an Unknown Number of Jobs in Restructuring

Post author:Sam
Post published:January 25, 2018
Post category:BioPharma

Novelion will slash an unknown number of jobs as it initiates "significant cost reduction plans." Source: BioSpace

Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs

Post author:Sam
Post published:January 25, 2018
Post category:BioPharma

The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace

J&J Bows Out of Race for Pfizer's $20B Consumer Health Biz

Post author:Sam
Post published:January 25, 2018
Post category:BioPharma

Now insiders say J&J has decided it is no longer interested. Source: BioSpace

FDA Warns Australian Firm for GMP Violations

Post author:Sam
Post published:January 25, 2018
Post category:Drug Industry Daily

The FDA hit Australian drugmaker Delta Laboratories with a warning letter for significant violations, including unreliable manufacturing processes, flawed stability testing and a lack of stability data. Source: Drug Industry…

FDA, Endo Pause Bulk Compounding Lawsuit Pending FDA Guidance

Post author:Sam
Post published:January 25, 2018
Post category:Drug Industry Daily

The FDA filed a joint motion with Endo to pause the company’s lawsuit accusing the agency of breaking the law with its decree authorizing bulk compounding of drugs. Source: Drug…

FDA Guidance on Combination Hypertension Drugs Offers Alternatives to Larger Trials

Post author:Sam
Post published:January 25, 2018
Post category:Drug Industry Daily

Drug sponsors can prove the effectiveness of combination drugs for treatment of hypertension with trials that test the highest approved dosage rather than trials with multiple doses, the FDA said…

FDA Drops Biennial Inspection Requirement for Biologics

Post author:Sam
Post published:January 25, 2018
Post category:Drug Industry Daily

The FDA issued a direct final rule removing the biennial inspection requirement for biologics production facilities and adopting a more flexible, risk-based approach to how often the agency will conduct…

Cellectis CEO Provides Update on UCART Programs and ‘Laser Focus’ of Company in 2018

Post author:Sam
Post published:January 24, 2018
Post category:BioPharma

After a brief stumble with UCART123 that resulted in a clinical hold last year, Cellectis is moving on with its study. Source: BioSpace